H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $36 from $35 and keeps a Buy rating on the shares following the Q4 report. The firm sees clinical data catalysts in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
Questions or Comments about the article? Write to editor@tipranks.com